Alpa Laboratories Ltd
NSE: ALPA BSE: 532878
Alpa Laboratories Ltd (ALPA) is a Diversified company listed on NSE: ALPA | BSE: 532878. With a market cap of ₹146 Cr and ROCE of 15%, ROE of 11.5%, it operates in the Indian Diversified sector.
₹69.2
52W: ₹46 — ₹120
PE 12.4 · Book ₹92 · -25% vs bookMarket Cap₹146 Cr
Stock P/E12.4Price to Earnings
ROCE15%Return on Capital
ROE11.5%Return on Equity
Div. Yield0%Face Value ₹10
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
- +Stock is trading at 0.76 times its book value
- +Company has delivered good profit growth of 29.6% CAGR over last 5 years
Weaknesses
- −Though the company is reporting repeated profits, it is not paying out dividend
- −The company has delivered a poor sales growth of 5.24% over past five years.
- −Company has a low return on equity of 10.7% over last 3 years.
- −Earnings include an other income of Rs.19.2 Cr.
- −Company has high debtors of 155 days.
Shareholding Pattern
Promoters57.19%
FIIs0.38%
DIIs0%
Public42.43%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.29% | 57.19%▼0.1 |
| FIIs | 0.36% | 0.74%▲0.4 | 0.35%▼0.4 | 0.4%▲0.1 | 0.36%▼0.0 | 0.35%▼0.0 | 0.36%▲0.0 | 0.38%▲0.0 |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 42.35% | 41.97%▼0.4 | 42.34%▲0.4 | 42.3%▼0.0 | 42.34%▲0.0 | 42.36%▲0.0 | 42.35%▼0.0 | 42.43%▲0.1 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 32.39 | 27.31 | 23.61 | 21.44 | 24.94 | 26.15 | 39.11 | 19.11 | 25.63 | 29.67 |
| Expenses | 29.07 | 24.85 | 20.1 | 20.9 | 21.67 | 25.41 | 39.47 | 18.69 | 28.5 | 27.53 |
| Operating Profit | 3.32 | 2.46 | 3.51 | 0.54 | 3.27 | 0.74 | -0.36 | 0.42 | -2.87 | 2.14 |
| OPM % | 10.25% | 9.01% | 14.87% | 2.52% | 13.11% | 2.83% | -0.92% | 2.2% | -11.2% | 7.21% |
| Net Profit | 5.74 | 4.53 | 3.55 | 5.12 | 7.63 | 8.89 | -1.95 | 11.78 | 0.1 | 1.87 |
| EPS ₹ | 2.73 | 2.15 | 1.69 | 2.43 | 3.63 | 4.23 | -0.93 | 5.6 | 0.05 | 0.89 |
AI Insights
Revenue Trend
TTM revenue at ₹114Cr, up 3.6% YoY. OPM at -1%.
Debt Position
Borrowings at ₹2Cr. Debt-to-equity ratio: 0.01x. Healthy balance sheet.
Institutional Flow
DIIs: 0% (-0.01pp change). FIIs: 0.38% (+0.38pp change). Promoters hold 57.19%.
Margin & Efficiency
ROCE improving from -3% (Mar 2014) to 15% (Mar 2025). Working capital days: 108.
Valuation
PE 12.4x with 15% ROCE. Price is -25% above book value of ₹92. Dividend yield: 0%.
Recent Announcements
- Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And Regulation 30 Of The SEBI (LODR) Regulations, 2015. 12 May - Board meets on 29 May 2026 to approve audited FY2026 standalone and consolidated results.
- Appointment of Company Secretary and Compliance Officer 11 Apr - Alpa Laboratories appoints Ms. Yashoda Patidar as Company Secretary and Compliance Officer from 11 April 2026.
- Clarification 9 Apr - Alpa Laboratories clarifies no undisclosed price-sensitive event or near-term announcement exists.
- Clarification Sought from Alpa Laboratories Ltd 8 Apr - Exchange has sought clarification from Alpa Laboratories Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors …
- Closure of Trading Window 20 Mar
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse